Is a
Product attributes
Industry
Product Parent Company
For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have activating epidermal growth factor receptor (EGFR) mutations. For the treatment of patients with locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum based chemotherapy.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
